State Street Corp Purchases 632,811 Shares of Eli Lilly and Company $LLY

State Street Corp lifted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 1.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,848,565 shares of the company’s stock after purchasing an additional 632,811 shares during the quarter. Eli Lilly and Company comprises about 1.2% of State Street Corp’s investment portfolio, making the stock its 11th biggest position. State Street Corp owned about 3.92% of Eli Lilly and Company worth $42,636,738,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in LLY. Torren Management LLC increased its stake in Eli Lilly and Company by 357.1% in the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after acquiring an additional 25 shares during the last quarter. Foresight Capital Management Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter worth approximately $49,000. Caitlin John LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $64,000. IMG Wealth Management Inc. boosted its position in shares of Eli Lilly and Company by 500.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock valued at $72,000 after acquiring an additional 50 shares during the last quarter. Finally, John Boyer Inc. purchased a new position in shares of Eli Lilly and Company in the third quarter valued at $72,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,346.40 on Friday. The stock has a 50 day moving average price of $1,268.06 and a 200 day moving average price of $1,119.25. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,475.25. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The firm has a market capitalization of $1.27 trillion, a P/E ratio of 43.70, a P/E/G ratio of 1.71 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the prior year, the company posted $7.02 EPS. Eli Lilly and Company’s quarterly revenue was up 38.6% on a year-over-year basis. As a group, sell-side analysts predict that Eli Lilly and Company will post 35.72 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Analyst Ratings Changes

LLY has been the topic of several research reports. The Goldman Sachs Group restated a “buy” rating and issued a $1,413.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. Bank of America reiterated a “buy” rating and set a $1,497.00 price objective on shares of Eli Lilly and Company in a research report on Friday, October 30th. Berenberg Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective for the company in a research note on Tuesday, September 15th. Truist Financial restated a “buy” rating and issued a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday, October 30th. Finally, Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research report on Friday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,422.00.

View Our Latest Report on LLY

Recent Eli Lilly and Company Headlines

Investors following LLY have been watching these headlines:

  • Neutral Sentiment: Recent updates cover studies of brenipatide, LY3839056, tirzepatide, and the cost of Alzheimer’s care. The reports describe study activity or updates, but the supplied information does not identify new efficacy results, so their near-term effect on valuation is unclear. Article: Lilly tests brenipatide in a depression study
  • Negative Sentiment: Some coverage warns that Lilly’s roughly $1.4 trillion valuation leaves substantial expectations embedded in the shares. That could make the stock more sensitive to any slowdown in growth or disappointing clinical results. Article: Eli Lilly’s valuation is heavy with hope
  • Negative Sentiment: Healthcare ETFs reportedly sold Lilly shares, including $17.4 million from IYH and $42.3 million from XLV. These sales may add some market pressure, though they appear to be fund-position changes rather than a company-specific development. Article: IYH sells Eli Lilly shares

Insider Buying and Selling

In related news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. This trade represents a 54.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.